Generalized myasthenia gravis: Clinical trials to watch.

IF 13.3 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2026-09-11 DOI:10.1016/j.medj.2026.101270

Sarah Hoffmann, Paolo Doksani, James F Howard

引用次数: 0

Abstract

Generalized myasthenia gravis is undergoing a highly dynamic phase of therapeutic development, with ongoing trials increasingly targeting upstream immune mechanisms. This Trial Watch highlights six studies evaluating B cell survival modulation, lymphocyte-directed immune reconstitution, BCMA- and CD19-directed CAR-T cell therapy, T cell engagement, and response-guided combination therapy, and considers their implications for future treatment strategies.

查看原文本刊更多论文

广泛性重症肌无力：临床试验值得关注。

广泛性重症肌无力正在经历一个高度动态的治疗发展阶段，正在进行的试验越来越多地针对上游免疫机制。本试验观察重点介绍了6项评估B细胞存活调节、淋巴细胞定向免疫重建、BCMA和cd19定向CAR-T细胞治疗、T细胞接合和反应引导联合治疗的研究，并考虑了它们对未来治疗策略的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.